Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient data for 8135 women in 22 randomised trials

Abstract

Background: Postmastectomy radiotherapy was shown in previous meta-analyses to reduce the risks of both recurrence and breast cancer mortality in all women with node-positive disease considered together. However, the benefit in women with only one to three positive lymph nodes is uncertain. We aimed to assess the effect of radiotherapy in these women after mastectomy and axillary dissection.

Methods: We did a meta-analysis of individual data for 8135 women randomly assigned to treatment groups during 1964-86 in 22 trials of radiotherapy to the chest wall and regional lymph nodes after mastectomy and axillary surgery versus the same surgery but no radiotherapy. Follow-up lasted 10 years for recurrence and to Jan 1, 2009, for mortality. Analyses were stratified by trial, individual follow-up year, age at entry, and pathological nodal status.

Findings: 3786 women had axillary dissection to at least level II and had zero, one to three, or four or more positive nodes. All were in trials in which radiotherapy included the chest wall, supraclavicular or axillary fossa (or both), and internal mammary chain. For 700 women with axillary dissection and no positive nodes, radiotherapy had no significant effect on locoregional recurrence (two-sided significance level [2p]>0·1), overall recurrence (rate ratio [RR], irradiated vs not, 1·06, 95% CI 0·76-1·48, 2p>0·1), or breast cancer mortality (RR 1·18, 95% CI 0·89-1·55, 2p>0·1). For 1314 women with axillary dissection and one to three positive nodes, radiotherapy reduced locoregional recurrence (2p<0·00001), overall recurrence (RR 0·68, 95% CI 0·57-0·82, 2p=0·00006), and breast cancer mortality (RR 0·80, 95% CI 0·67-0·95, 2p=0·01). 1133 of these 1314 women were in trials in which systemic therapy (cyclophosphamide, methotrexate, and fluorouracil, or tamoxifen) was given in both trial groups and, for them, radiotherapy again reduced locoregional recurrence (2p<0·00001), overall recurrence (RR 0·67, 95% CI 0·55-0·82, 2p=0·00009), and breast cancer mortality (RR 0·78, 95% CI 0·64-0·94, 2p=0·01). For 1772 women with axillary dissection and four or more positive nodes, radiotherapy reduced locoregional recurrence (2p<0·00001), overall recurrence (RR 0·79, 95% CI 0·69-0·90, 2p=0·0003), and breast cancer mortality (RR 0·87, 95% CI 0·77-0·99, 2p=0·04).

Interpretation: After mastectomy and axillary dissection, radiotherapy reduced both recurrence and breast cancer mortality in the women with one to three positive lymph nodes in these trials even when systemic therapy was given. For today's women, who in many countries are at lower risk of recurrence, absolute gains might be smaller but proportional gains might be larger because of more effective radiotherapy.

Funding: Cancer Research UK, British Heart Foundation, UK Medical Research Council.

Copyright © 2014 EBCTCG. Open Access article distributed under the terms of CC BY. Published by Elsevier Ltd. All rights reserved.

Figures

Figure 1

Trials included in analysis

Figure 2

Effect of radiotherapy (RT) after mastectomy and axillary dissection (Mast+AD) on 10-year risks of locoregional and overall recurrence and on 20-year risk of breast cancer mortality in 700 women with pathologically node-negative (pN0) disease and in 3131 women with pathologically node-positive (pN+) disease Analyses of locoregional recurrence first ignore distant recurrences, see appendix pp 8–9 for details. See appendix pp 14, 16, for analyses of both locoregional and distant recurrences, and appendix pp 13, 15, for analyses of overall mortality. RR=rate ratio. NS=not significant. Vertical lines indicate 1 SE above or below the 5, 10, 15, and 20 year percentages.

Figure 3

Effect of radiotherapy (RT) after mastectomy and axillary dissection (Mast+AD) on 10-year risks of locoregional and overall recurrence and on 20-year risk of breast cancer mortality in 1314 women with one to three pathologically positive nodes (pN1–3) and in 1772 women with four or more pathologically positive nodes (pN4+) Analyses of locoregional recurrence first ignore distant recurrences, see appendix pp 8–9 for details. See appendix pp 19, 28, for analyses of both locoregional and distant recurrences, and appendix pp 18, 27, for analyses of overall mortality. RR=rate ratio. NS=not significant. Vertical lines indicate 1 SE above or below the 5, 10, 15, and 20 year percentages.

Figure 4

Effect of radiotherapy (RT) after mastectomy and axillary dissection on overall recurrence during years 0–9 and on breast cancer mortality for the entire follow-up in 1314 women with one to three pathologically positive nodes, according to whether or not they were in trials in which systemic therapy was given to both randomised treatment groups Chemotherapy was usually cyclophosphamide, methotrexate, and fluorouracil. ER-negative women in trials in which tamoxifen was given to both groups are included in the “no systemic” category. ER=oestrogen receptor. tam=tamoxifen. NS=not significant. SE=standard error.

Figure 5

Effect of radiotherapy (RT) after mastectomy and axillary dissection (Mast+AD) on 10-year risks of locoregional and overall recurrence and on 20-year risk of breast cancer mortality in 1133 women with one to three pathologically positive nodes (pN1–3) in trials in which systemic therapy was given to both randomised treatment groups Analyses of locoregional recurrence first ignore distant recurrences, see appendix pp 8–9 for details. See appendix p 22 for analyses of both locoregional and distant recurrences, and appendix p 21 for analyses of overall mortality. RR=rate ratio. Vertical lines indicate 1 SE above or below the 5, 10, 15, and 20 year percentages.

Figure 6

Effect of radiotherapy (RT) after mastectomy and axillary dissection on overall recurrence during years 0–9 and on breast cancer mortality for the entire follow-up in 1133 women with one to three pathologically positive nodes (pN1–3) in trials in which systemic therapy was given to both randomised treatment groups, by number of positive nodes See also appendix pp 23–26. NS=not significant. SE=standard error.